| Applications: | Immunodepletion/Immunocompetition |
| Note: | STRICTLY FOR FURTHER SCIENTIFIC RESEARCH USE ONLY (RUO). MUST NOT TO BE USED IN DIAGNOSTIC OR THERAPEUTIC APPLICATIONS. |
| Short Description : | TRIF Blocking Peptide is synthetically produced from the 150-199 sequence and is suitable for use in western blot applications. |
| Formulation: | Liquid form at 2.5mg/ml concentration in PBS. Up to 5% DMSO can be added. Orders with >1mg can be supplied in lyophilized powder form, or in buffer of choice. |
| Storage Instruction: | Store at-20°C for long term storage. Avoid freeze-thaw cycles. |
| Immunogen Region: | 150-199 |
| Immunogen: | Synthetic peptide taken within amino acid region 150-199 on human E3 ubiquitin-protein ligase RNF138 protein. |
| Background | E3 ubiquitin-protein ligase. Together with NLK, involved in the ubiquitination and degradation of TCF/LEF. Also exhibits auto-ubiquitination activity in combination with UBE2K. May act as a negative regulator in the Wnt/beta-catenin-mediated signaling pathway (By similarity). |
Information sourced from Uniprot.org